NeuroMetrix, Inc.
NURO · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.99 | 0.02 | -0.01 |
| FCF Yield | -23.21% | -22.32% | -18.73% | -28.29% |
| EV / EBITDA | -3.96 | -4.31 | -3.37 | -2.10 |
| Quality | ||||
| ROIC | -13.57% | -10.81% | -10.37% | -17.16% |
| Gross Margin | 61.56% | 53.12% | 63.96% | 47.28% |
| Cash Conversion Ratio | 1.06 | 1.19 | 0.92 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.38% | -22.92% | -19.25% | -14.39% |
| Free Cash Flow Growth | -5.44% | -31.37% | 34.44% | -39.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.77 | 0.46 | 0.82 | 0.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.17 | 0.19 | 0.19 | 0.39 |
| Cash Conversion Cycle | 425.15 | 376.65 | 401.75 | 245.78 |